Creating advanced antibody technologies for better disease diagnosis and treatment
Development of the next generation antibody technologies and their applications
This study is working on creating better, more reliable antibodies called Nanobodies that could lead to improved tests and treatments for patients, making sure that research results are more consistent and effective.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10912512 on NIH RePORTER |
What this research studies
This research focuses on developing next-generation antibody technologies, specifically targeting the creation of high-quality antibodies known as Nanobodies. These antibodies are designed to overcome current challenges in antibody production, such as low affinity and batch-to-batch variability, which can lead to unreliable research results. By utilizing a robust pipeline for discovering and characterizing these antibodies, the research aims to enhance their application in biomedical research and drug therapeutics. Patients may benefit from improved diagnostic tools and therapies that arise from these advancements.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research include individuals with conditions that require precise diagnostic methods or targeted therapies.
Not a fit: Patients with conditions that do not involve antibody-based diagnostics or treatments may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more reliable diagnostic tools and effective treatments for various diseases.
How similar studies have performed: Previous research has shown promise in developing advanced antibody technologies, indicating that this approach has the potential for significant breakthroughs.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Shi, Yi — Icahn School of Medicine at Mount Sinai
- Study coordinator: Shi, Yi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.